SUMMARY

• RYBREVANT (amivantamab-vmjw) is a low fucose, fully human immunoglobulin G1 (IgG1)-based bispecific antibody with immune cell-directing activity that targets epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition (MET) mutations and amplifications in non-small cell lung cancer (NSCLC).¹
• No clinically meaningful differences in the pharmacokinetics (PK) of amivantamab-vmjw were observed based on mild hepatic impairment ([total bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN] or [ULN < total bilirubin ≤1.5 times ULN]). The effect of moderate to severe hepatic impairment (total bilirubin >1.5 times ULN and any AST) on amivantamab-vmjw PK has not been studied.²
• Please refer to RYBREVANT product labeling for additional information.²

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 10 February 2026.